Germany
Japan
United Kingdom
China
Antibodies
USD 479.00
2 Weeks
HER2 (ERBB2) Mouse Monoclonal Antibody, clone 3C2-4
| Applications | FC |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
HER2 (ERBB2) Mouse Monoclonal Antibody, clone 3G11-14
| Applications | FC |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
HER2 (ERBB2) Mouse Monoclonal Antibody, clone 4A5-19
| Applications | FC |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
HER2 (ERBB2) Mouse Monoclonal Antibody, clone 5F4-15
| Applications | FC |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
HER2 (ERBB2) Mouse Monoclonal Antibody, clone 5G12-21
| Applications | FC |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
HER2 (ERBB2) Mouse Monoclonal Antibody, clone 6F5-23
| Applications | FC |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
HER2 (ERBB2) Mouse Monoclonal Antibody, clone 6H8-22
| Applications | FC |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
HER2 (ERBB2) Mouse Monoclonal Antibody, clone 8E8-2
| Applications | FC |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
HER2 (ERBB2) Mouse Monoclonal Antibody, clone 8F6-6
| Applications | FC |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
HER2 (ERBB2) Mouse Monoclonal Antibody, clone 9G5-20
| Applications | FC |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
HER2 (ERBB2) Mouse Monoclonal Antibody, clone 12G4-15
| Applications | FC |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
HER2 (ERBB2) Mouse Monoclonal Antibody, clone 15C4-8
| Applications | FC |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
HER2 (ERBB2) Mouse Monoclonal Antibody, clone 16F12-11
| Applications | FC |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
USD 524.00
In Stock
USD 440.00
2 Weeks
Mouse Anti-Human IL-1 beta Purified (50 ug)
| Applications | FC |
| Reactivities | Human |
| Conjugation | Unconjugated |
Mouse Monoclonal iNOS Antibody (4E5)
| Applications | ELISA, FC, IHC, WB |
| Reactivities | Human, Mouse |
| Conjugation | Unconjugated |
TA336918 is a replacement of AM06772PU-N.
USD 440.00
2 Weeks
LDL Receptor (LDLR) mouse monoclonal antibody, clone C7, Purified
| Applications | FC, IF, WB |
| Reactivities | Bovine, Human |
| Conjugation | Unconjugated |
Mouse monoclonal anti-ATP1A1(NaK ATPase) antibody, clone 464.6, Loading control
| Applications | FC, IHC, WB |
| Reactivities | Canine, Human, Mouse, Porcine, Primate, Rabbit, Rat, Sheep, Xenopus |
| Conjugation | Unconjugated |
Active filters
Category
-
Antibodies
- Primary Antibodies
Reactivities
- Human
Applications
- FC
Clonalities
- Monoclonal
Conjugates
- Unconjugated
Filter by
Target Symbol
- PDCD1 (123)
- CD5 (109)
- CTAG1B (72)
- HAVCR2 (70)
- ERCC1 (69)
- LIPG (63)
- PECAM1 (61)
- CD274 (56)
- L1CAM (53)
- CD47 (51)
- CTNNB1 (51)
- PDCD1LG2 (50)
- TNFRSF8 (49)
- TP53 (48)
- CD33 (46)
- CTLA4 (45)
- ERBB2 (45)
- CD99 (42)
- TIGIT (42)
- ICOS (41)
- LGR5 (40)
- CD40 (39)
- FGF21 (39)
- LRATD2 (39)
- PNMT (39)
- SENP2 (39)
- LAG3 (37)
- AFP (35)
- TNFRSF9 (35)
- CD63 (34)
- CD80 (34)
- SQSTM1 (34)
- ACAT2 (33)
- MICAL1 (33)
- RNF144B (33)
- TTC32 (33)
- TTLL12 (33)
- UBE2E3 (33)
- ZFP36 (33)
- PTPRC (31)
- BTK (30)
- BTLA (30)
- CD2 (30)
- CDK2 (30)
- HIBCH (30)
- IGF2BP2 (30)
- KATNB1 (30)
- LENG1 (30)
- MAPK7 (30)
- MAPRE2 (30)
- MEIS3 (30)
- MOB3B (30)
- NME4 (30)
- NPR3 (30)
- PACSIN3 (30)
- PDE4A (30)
- PFKP (30)
- PRKCE (30)
- RPN1 (30)
- SDR9C7 (30)
- SMS (30)
- TACC3 (30)
- ACY1 (27)
- AK5 (27)
- ARHGAP25 (27)
- BECN1 (27)
- BTN1A1 (27)
- CBWD1 (27)
- DSTN (27)
- EPM2AIP1 (27)
- EXD1 (27)
- GSTT2 (27)
- HOXC11 (27)
- LDLRAP1 (27)
- LIMK1 (27)
- LRRC25 (27)
- NRBP1 (27)
- NT5DC1 (27)
- PDE2A (27)
- PIK3AP1 (27)
- SIRT5 (27)
- SNAP25 (27)
- SNX9 (27)
- SRR (27)
- STAT5A (27)
- TAL1 (27)
- TUBAL3 (27)
- CD27 (26)
- ACY3 (24)
- AK4 (24)
- ARFGAP1 (24)
- ATP5F1B (24)
- CD4 (24)
- CD86 (24)
- CHCHD5 (24)
- CRYAB (24)
- DNAJA2 (24)
- ERCC4 (24)
- FBXO21 (24)
- FSHB (24)
Antibody Hosts
Isotypes
Knockout (KO) Validation
Modifications
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques. (47)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. (17)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (16)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG1 format, for improved compatibility with existing reagents, assays and techniques. (16)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. (12)
- This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (10)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2b format, for improved compatibility with existing reagents, assays and techniques. (9)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human Fab format, for improved compatibility with existing reagents, assays and techniques. (7)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG2a format, for improved compatibility with existing reagents, assays and techniques. (5)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. (4)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgM format, for improved compatibility with existing reagents, assays and techniques. (4)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG2a format, for improved compatibility with existing reagents, assays and techniques. (4)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (3)
- This full-length, chimeric rabbit antibody was made using the variable domain sequences of the original Mouse scFv format, for improved compatibility with existing reagents, assays and techniques. (3)
- Phospho-specific (2)
- This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG3 format, for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG2b format, for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG2b format, for improved compatibility with existing reagents, assays and techniques. (2)
- This full-length, reformatted mouse antibody was made using the variable domain sequences of the original Mouse scFv format, for improved compatibility with existing reagents, assays and techniques. (2)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This reformatted human antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric human antibody was made using the variable domain sequences of the original IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric murine antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Hamster IgG format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgM format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original rat IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This is a chimeric mouse antibody, based on the original rat IgG2b format, created for improved compatibility with existing reagents, assays and techniques. (1)
- This is a reformatted human IgG1 antibody based on the therapeutic Fab fragment. NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. (1)
- This reformatted mouse antibody was made using the variable domain sequences of the original mouse scFv format for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted rat antibody was made using the variable domain sequences of the original Rat IgG format, for improved compatibility with existing reagents, assays and techniques. (1)
Assay Types
Families
- Druggable Genome (6013)
- Transmembrane (2649)
- Transcription Factors (952)
- ES Cell Differentiation/IPS (813)
- Secreted Protein (647)
- Protease (529)
- Protein Kinase (501)
- Stem cell - Pluripotency (373)
- Phosphatase (176)
- Adult stem cells (171)
- Embryonic stem cells (94)
- P450 (93)
- Ion Channels: Other (69)
- Stem cell relevant signaling - DSL/Notch pathway (60)
- GPCR (56)
- Stem cell relevant signaling - JAK/STAT signaling pathway (55)
- Cancer stem cells (41)
- Induced pluripotent stem cells (30)
- Nuclear Hormone Receptor (27)
- Ion Channels: Potassium (18)
- Stem cell relevant signaling - TGFb/BMP signaling pathway (12)
- Stem cell relevant signaling - Wnt Signaling pathway (5)
Pathways
- Metabolic pathways (1300)
- Cell adhesion molecules (CAMs) (715)
- Pathways in cancer (496)
- Hematopoietic cell lineage (377)
- T cell receptor signaling pathway (348)
- MAPK signaling pathway (336)
- Cytokine-cytokine receptor interaction (314)
- Purine metabolism (264)
- Prostate cancer (251)
- Leukocyte transendothelial migration (244)
- Progesterone-mediated oocyte maturation (238)
- Focal adhesion (232)
- Cell cycle (216)
- Toll-like receptor signaling pathway (215)
- Regulation of actin cytoskeleton (209)
- Endometrial cancer (204)
- Neurotrophin signaling pathway (204)
- Chronic myeloid leukemia (197)
- Colorectal cancer (195)
- Huntington's disease (191)
- Pancreatic cancer (188)
- Primary immunodeficiency (188)
- Insulin signaling pathway (185)
- Alzheimer's disease (178)
- Fc gamma R-mediated phagocytosis (177)
- Non-small cell lung cancer (177)
- Melanoma (176)
- Apoptosis (175)
- Adherens junction (174)
- Jak-STAT signaling pathway (169)
- ErbB signaling pathway (167)
- Wnt signaling pathway (166)
- Endocytosis (164)
- Systemic lupus erythematosus (164)
- Glycolysis / Gluconeogenesis (163)
- Pathogenic Escherichia coli infection (157)
- Ubiquitin mediated proteolysis (156)
- Bladder cancer (155)
- Small cell lung cancer (154)
- Autoimmune thyroid disease (146)
- Tight junction (145)
- B cell receptor signaling pathway (142)
- Pyruvate metabolism (139)
- Glioma (134)
- Nucleotide excision repair (131)
- Arginine and proline metabolism (128)
- Thyroid cancer (128)
- Glycerolipid metabolism (127)
- p53 signaling pathway (125)
- Fc epsilon RI signaling pathway (124)
- Axon guidance (123)
- Adipocytokine signaling pathway (118)
- Viral myocarditis (118)
- Acute myeloid leukemia (116)
- Valine (115)
- Allograft rejection (113)
- Gap junction (113)
- Parkinson's disease (113)
- Oxidative phosphorylation (112)
- Drug metabolism - cytochrome P450 (111)
- Oocyte meiosis (109)
- leucine and isoleucine degradation (109)
- Fructose and mannose metabolism (105)
- Basal cell carcinoma (102)
- Metabolism of xenobiotics by cytochrome P450 (102)
- Type II diabetes mellitus (102)
- ECM-receptor interaction (100)
- Arrhythmogenic right ventricular cardiomyopathy (ARVC) (96)
- Tyrosine metabolism (96)
- Pyrimidine metabolism (90)
- Renal cell carcinoma (88)
- Glycine (87)
- Proteasome (87)
- serine and threonine metabolism (87)
- Graft-versus-host disease (84)
- Chemokine signaling pathway (81)
- Natural killer cell mediated cytotoxicity (81)
- Type I diabetes mellitus (81)
- Amyotrophic lateral sclerosis (ALS) (80)
- Glutathione metabolism (77)
- GnRH signaling pathway (77)
- mTOR signaling pathway (77)
- Propanoate metabolism (76)
- Tryptophan metabolism (73)
- Calcium signaling pathway (72)
- Retinol metabolism (72)
- TGF-beta signaling pathway (69)
- Cysteine and methionine metabolism (67)
- Histidine metabolism (67)
- beta-Alanine metabolism (67)
- Fatty acid metabolism (64)
- Melanogenesis (62)
- Pentose phosphate pathway (61)
- Arachidonic acid metabolism (60)
- Antigen processing and presentation (59)
- Lysosome (59)
- VEGF signaling pathway (59)
- Butanoate metabolism (58)
- Vascular smooth muscle contraction (58)
- Epithelial cell signaling in Helicobacter pylori infection (53)
- Renin-angiotensin system (53)
- Citrate cycle (TCA cycle) (50)
- Regulation of autophagy (50)
- Lysine degradation (49)
- Nicotinate and nicotinamide metabolism (48)
- Terpenoid backbone biosynthesis (48)
- Hypertrophic cardiomyopathy (HCM) (47)
- Asthma (46)
- NOD-like receptor signaling pathway (46)
- Dilated cardiomyopathy (45)
- Glyoxylate and dicarboxylate metabolism (45)
- PPAR signaling pathway (44)
- Amino sugar and nucleotide sugar metabolism (42)
- Linoleic acid metabolism (42)
- Starch and sucrose metabolism (42)
- Synthesis and degradation of ketone bodies (42)
- Porphyrin and chlorophyll metabolism (39)
- Complement and coagulation cascades (38)
- DNA replication (37)
- Mismatch repair (37)
- Alanine (36)
- Galactose metabolism (36)
- Neuroactive ligand-receptor interaction (36)
- RIG-I-like receptor signaling pathway (36)
- aspartate and glutamate metabolism (36)
- Vibrio cholerae infection (34)
- Caffeine metabolism (33)
- Cardiac muscle contraction (33)
- N-Glycan biosynthesis (33)
- Long-term depression (31)
- Notch signaling pathway (31)
- Cytosolic DNA-sensing pathway (30)
- Inositol phosphate metabolism (30)
- RNA degradation (30)
- Ascorbate and aldarate metabolism (28)
- Prion diseases (28)
- Androgen and estrogen metabolism (27)
- Maturity onset diabetes of the young (27)
- One carbon pool by folate (27)
- SNARE interactions in vesicular transport (27)
- Drug metabolism - other enzymes (24)
- Non-homologous end-joining (24)
- Long-term potentiation (22)
- Spliceosome (22)
- Cyanoamino acid metabolism (21)
- Folate biosynthesis (21)
- Homologous recombination (21)
- Selenoamino acid metabolism (21)
- Sulfur metabolism (21)
- Pantothenate and CoA biosynthesis (18)
- Phosphatidylinositol signaling system (18)
- Base excision repair (17)
- ABC transporters (12)
- Aminoacyl-tRNA biosynthesis (12)
- Basal transcription factors (12)
- Glycosaminoglycan degradation (12)
- Phenylalanine metabolism (12)
- RNA polymerase (12)
- Vitamin B6 metabolism (12)
- Nitrogen metabolism (10)
- Biosynthesis of unsaturated fatty acids (9)
- Circadian rhythm - mammal (9)
- Glycerophospholipid metabolism (9)
- Hedgehog signaling pathway (9)
- Methane metabolism (9)
- Riboflavin metabolism (9)
- Thiamine metabolism (9)
- Limonene and pinene degradation (7)
- Other glycan degradation (6)
- Pentose and glucuronate interconversions (6)
- Sphingolipid metabolism (6)
- leucine and isoleucine biosynthesis (6)
- Dorso-ventral axis formation (5)
- Glycosphingolipid biosynthesis - lacto and neolacto series (4)
- Biotin metabolism (3)
- C21-Steroid hormone metabolism (3)
- Glycosphingolipid biosynthesis - ganglio series (3)
- Keratan sulfate biosynthesis (3)
- Olfactory transduction (3)
- Steroid biosynthesis (3)